Abstract 46P
Background
Breast cancer is one of the malignant diseases with the highest prevalence around the world, including Indonesia. Data from Global Cancer Statistics 2018 (GLOBOCAN) predicted that up to 2.1 billion women were diagnosed with breast cancer; therefore, it became one of the top four cancerous diseases in women. Several studies have revealed the role of CD36 molecule in breast cancer and there are several gaps in CD36 expression knowledge. In tumor adhesion, CD36 is involved in cellular interaction with collagen in the extracellular matrix. Some measurement methods of CD36 expression molecules include gene expression measurement through micro-assay, total RNA analysis, and plasma examination through ELISA techniques already done in subjects with non alcoholic fatty liver disease, diabetes mellitus, insulin resistance, coronary arterial disease, carotid atherosclerosis, chronic kidney disease, and ischaemic stroke. However, concentration measurement of CD36 plasma molecule in breast cancer using ELISA technique has not yet been done in previous studies.
Methods
This is a cross-sectional study, was held during June 2018 up to February 2019. Sampling methods were taken consecutively in 118 subjects, consisted of 76 BC subjects, 42 normal subjects. Inclusion criteria included women aged 18 to 70 years old, having pathological invasive breast cancers, and subjects were willing to sign the informed consent sheets. Exclusion criteria included subjects with disease progressivity during therapy, diabetes mellitus, stroke, liver, coronary arterial disease, chronic kidney disease. Subjects were then drawn 2 cc of the peripheral blood,and then was centrifuged in 3000 RPM for 15 minutes. After that, the plasma was analyzed with ELISA technique with reagent (Bioassay Technology Laboratory). Data was analyzed using SPSS for windows version 20.
Results
Table: 46P
Profile of plasma CD36 concentration
Characteristic | Median concentration CD36 (ng/mL) | p |
---|---|---|
BC Healthy | 0.21 (-0.05 up to 0.70) 0.57 (0.13 up to 1.05) | 0.00 |
Metastatic BC Non metastatic BC | 0.21 (-0.05 up to 0.70) 0.21 (-0.05 up to 0.70) | > 0.05 |
BC with LN metastatic BC without LN metastatic | 0.20 (-0.05 up to 0.70) 0.23 (-0.05 up to 0.70) | > 0.05 |
Luminal tumor HER2 tumor Triple negative tumor | 0.21 (-0.05 up to 0.67) 0.21 (-0.02 up to 0.70) 0.22 (-0.02 up to 0.36) | > 0.05 |
G1 G2 G3 Unknown grade | 0.23 (0.16 up to 0.70) 0.21 (-0.05 up to 0.70) 0,20 (-0,02 up to 0,67) 0.22 (0.10 up to 0.53) | > 0.05 |
Tumor size > 2 cm Tumor size ≤ 2 cm | 0.21 (-0.05 up to 0.70) 0.26 (0.13 up to 0.70) | > 0.05 |
BC with BMI≥ 23 BC with BMI < 23 | 0.20 (-0.05 up to 0.70) 0.23 (-0.05 up to 0.70) | > 0.05 |
Conclusions
Plasma CD36 concentration of breast cancer is lower than the healthy. There are insignificant differences of plasma CD36 concentration profile breast cancer patients based on metastatic status, lymph node metastatic, molecular subtype, invasive cancer histologic grade, and body mass index.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Ethics Committee of The Faculty of Medicine, University of Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
Presenter: Radka Obermannova
Session: Poster display session
Resources:
Abstract
145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
Presenter: Toshikazu Moriwaki
Session: Poster display session
Resources:
Abstract
146P - Anatomic versus non-anatomic resection for hepatocellular carcinoma: A meta-analysis of high-quality studies
Presenter: Bin Zhang
Session: Poster display session
Resources:
Abstract
147P - Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis
Presenter: Yingtai Chen
Session: Poster display session
Resources:
Abstract
148P - Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Presenter: Seunghwan Lee
Session: Poster display session
Resources:
Abstract
150P - A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Presenter: Yee Chao
Session: Poster display session
Resources:
Abstract
151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement
Presenter: Midie Xu
Session: Poster display session
Resources:
Abstract
152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma
Presenter: Chia-Lun Chang
Session: Poster display session
Resources:
Abstract
153P - Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis
Presenter: Dening Ma
Session: Poster display session
Resources:
Abstract
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract